Please login to the form below

Not currently logged in
Email:
Password:

Takeda launches drug discovery biotech

Hopes Bridge Medicines will streamline the development process

TakedaTakeda has joined forces with three US academic institutions to launch a drug discovery company whose mission is to speed the development of innovative therapies.

New-York-based biotech Bridge Medicines will provide a fully-funded path from concept to drug candidate, eschewing time-consuming searches for investors and product licensers that can often bring a halt to a drug's development.

It builds on work from the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) - a partnership created in 2013 by the Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine.

Tri-I TDI currently has 50 early-stage research drug discovery projects underway and these will also benefit from Bridge Medicines' financial, operational and managerial support.

Dr Michael Foley, Sanders director of the Tri-I TDI, said: “The launch of Bridge Medicines is a truly exciting development in New York's biotechnology space.

“We're tapping into the distinguished talent at Sloan Kettering, Rockefeller and Weill Cornell Medicine and offering entrepreneurs access to support what's next in biopharmaceuticals.

“Bridge Medicines will enable us to advance promising projects farther down the development pipeline, providing new therapies to patients as quickly as possible.”

The collaboration between Takeda and the Tri-I TDI enables funding of potentially transformational but risky research projects thanks to the partnership's group model, which has the support of healthcare investment firms Bay City Capital and Deerfield Management.

Dr Foley added: “Bridge Medicines' mission is to increase the odds of successfully developing novel therapeutics to meet the needs of patients while simultaneously helping to build a vibrant biotechnology sector in New York City.”

Article by
Rebecca Clifford

1st November 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...

Infographics